From Nasdaq: 2024-06-06 10:21:00

Eli Lilly’s CFO, Anat Ashkenazi, resigns after 23 years to join Google’s parent company Alphabet as CFO and SVP starting Jul 31, 2024. Ruth Porat will continue as CFO until Ashkenazi’s transition. Lilly searches for a new CFO internally and externally. Lilly stock rose 42.7% year to date.

During Ashkenazi’s tenure, Lilly saw tremendous growth with stock rising 273.8% in 3 years, driven by drugs like Mounjaro, Verzenio, and new tirzepatide medicines. Ashkenazi’s move from healthcare to tech industry surprises investors. Her experience in healthcare may benefit Alphabet’s push into the healthcare sector.

ACRV and HRTX are better-ranked healthcare stocks with Zacks Rank 2 (Buy). ACRV beat estimates in 3 of the past 4 quarters with 50.2% stock rise YTD. Heron Therapeutics narrowed loss estimates and improved prospects for earnings in 2024 and 2025, with stock rising 124.7% YTD.

Bitcoin remains the most profitable asset class with significant returns in past election years and predicted surges ahead. Zacks forecasts further significant growth. Download the free special report for insights and recommendations from Zacks Investment Research.

For more insights and free stock analysis reports, visit Zacks Investment Research online. Make informed investment decisions with expert analysis and recommendations from Zacks.



Read more at Nasdaq: Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO